『This Week In Medicine』のカバーアート

This Week In Medicine

This Week In Medicine

著者: A.I.O.
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり

Welcome to This Week in Medicine - Your Filtered Medical Journal SummaryLooking to stay up-to-date with the latest medical research but short on time? This Week in Medicine has you covered!Our AI generated podcast provides you with a convenient, on-the-go solution to keep you informed about the most significant developments in the medicine field. We understand that your time is valuable, so we've done the hard work for you.Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers. With This Week in Medicine, listening is faster than reading, and you can consume valuable medical knowledge while commuting, exercising, or during your daily routine. Whether you're a busy healthcare professional, a medical student, or simply someone interested in staying informed about groundbreaking medical discoveries, This Week in Medicine is your go-to resource. Tune in to This Week in Medicine for a faster, more accessible, and engaging way to keep up with the ever-evolving world of Medicine.Subscribe now and join us on this journey to make medical knowledge accessible to everyone around the world at no cost!And always, please refer to the original article for accuracy and draw your own conclusions.

All rights reserved.
衛生・健康的な生活 身体的病い・疾患
エピソード
  • NEJM 10 1 2026 Giredestrant plus Everolimus in Advanced Breast Cancer
    2026/10/07

    Giredestrant plus Everolimus in Advanced Breast Cancer

    続きを読む 一部表示
    2 分
  • NEJM 10 1 2026 Obexelimab for the Treatment of IgG4-Related Disease
    2026/10/07

    A recent phase 3 clinical trial investigated obexelimab, a novel monoclonal antibody that suppresses B-cell function without destroying the cells, as a potential therapy for IgG4-related disease. Standard treatments typically rely on glucocorticoids, which often cause significant toxicity and frequently lead to relapses once stopped. To test the medication, 194 patients were randomly assigned to receive either weekly subcutaneous injections of obexelimab or a placebo while systematically tapering off steroids. The findings demonstrated that obexelimabsubstantially reduced the likelihood of disease flare-ups, prolonged the duration of remission, and lowered the overall requirement for rescue steroid medications compared to the placebo group. Ultimately, the study indicates that obexelimab offers a safer and more effective alternative for managing this chronic inflammatory condition while minimizing harmful steroid exposure.

    続きを読む 一部表示
    1 分
  • NEJM 10 1 2026 Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
    2026/10/07

    Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults

    続きを読む 一部表示
    2 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません